Roivant Sciences stock
ROIVNASDAQRoivant Sciences Ltd., HealthcareISIN BMG762791017
48Score 48 out of 100, Weak
Price and trend
88 / 100
Price history
+88% in one yearThe chart shows daily closes over 6 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 24% above it.
Since July 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 62).
The price is 4.4% below its 52-week high. Largest decline in 6 years: 79% (December 2021 to May 2022).
Chart figures for advanced users
- SMA 50$37.20
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$32.22
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)62
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$20.10
- The lowest closing price of the last twelve months.
- Resistance$41.85
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Roivant Sciences Ltd. belongs to the Biotechnology industry (United Kingdom) and, with a market value of $28.98B, is number 12 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $8.26M (down 71.6% year on year) and a loss of $299.77M.
- For fiscal 2026, analysts expect on average revenue of $57.27M (up 593.3%) and adjusted earnings per share of −$1.37.
Show more
- MEQIRI Score 48 out of 100 (Weak): rank 403 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $4.21B, financial debt $106.57M.Stability 81
Weaknesses
- Loss-makingLoss of $344.35M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$26.23M over the last 12 months.Fundamentals 17
- Revenue shrinkingRevenue down 7.6% a year since 2020.Growth 32
Its standout strengths are momentum and technical analysis, while capital allocation and fundamentals hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 47 to 48.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2025, revenue fell 71.6% on the prior year. Up to 2022 the bars include businesses that were later spun off or sold. On a comparable basis, as restated in the SEC annual reports, revenue shrank 7.6% a year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 84%, operating −15561%, net −3629%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- 5 Feb 2027in 84 days
- Last reported
- 9 Nov 2026EPS reported −$0.27 (expected −$0.37)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$1.37+0.4%
- Revenue
- $57.27M+9.9%
- Earnings per share
- −$1.30+0.7%
- Revenue
- $426.57M+4.7%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 7 insiders sold, $205.71M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Pulik RichardSale
11 Nov 2026, CFO
- Shares
- 175,000
- Price
- $41.85
- Value
- $7.32M
- Pulik RichardSale
10 Nov 2026, CFO
- Shares
- 125,000
- Price
- $41.20
- Value
- $5.15M
- Venker EricSale
10 Nov 2026, President & Immunovant CEO
- Shares
- 187,943
- Price
- $40.53
- Value
- $7.62M
Show 26 more
- Venker EricSale
3 Nov 2026, President & Immunovant CEO
- Shares
- 200,000
- Price
- $36.31
- Value
- $7.26M
- Venker EricSale
28 Oct 2026, President & Immunovant CEO
- Shares
- 200,000
- Price
- $36.59
- Value
- $7.32M
- Venker EricSale
20 Oct 2026, President & Immunovant CEO
- Shares
- 200,000
- Price
- $35.11
- Value
- $7.02M
- Epperly Melissa B,Sale
1 Oct 2026, Board
- Shares
- 17,750
- Price
- $36.10
- Value
- $640,861
- Venker EricSale
30 Sept 2026, President & Immunovant CEO
- Shares
- 200,000
- Price
- $36.62
- Value
- $7.32M
- Epperly Melissa B,Sale
15 Sept 2026, Board
- Shares
- 4,938
- Price
- $39.74
- Value
- $196,230
- Fitzgerald MeghanSale
15 Sept 2026, Board
- Shares
- 5,112
- Price
- $39.74
- Value
- $203,152
- Fitzgerald MeghanSale
8 Sept 2026, Board
- Shares
- 20,000
- Price
- $39.90
- Value
- $798,000
- Venker EricSale
28 Aug 2026, President & Immunovant CEO
- Shares
- 200,000
- Price
- $35.77
- Value
- $7.15M
- Sukhatme MayukhSale
21 Aug 2026, President & CIO
- Shares
- 144,756
- Price
- $36.48
- Value
- $5.28M
- Sukhatme MayukhSale
20 Aug 2026, President & CIO
- Shares
- 17,519
- Price
- $37.30
- Value
- $653,459
- Sukhatme MayukhSale
19 Aug 2026, President & CIO
- Shares
- 172,899
- Price
- $37.17
- Value
- $6.43M
- Sukhatme MayukhSale
18 Aug 2026, President & CIO
- Shares
- 136,942
- Price
- $36.73
- Value
- $5.03M
- Sukhatme MayukhSale
17 Aug 2026, President & CIO
- Shares
- 284,707
- Price
- $36.25
- Value
- $10.32M
- Sukhatme MayukhSale
14 Aug 2026, President & CIO
- Shares
- 243,177
- Price
- $36.23
- Value
- $8.81M
- Venker EricSale
27 Jul 2026, President & Immunovant CEO
- Shares
- 200,000
- Price
- $34.95
- Value
- $6.99M
- Fitzgerald MeghanSale
30 Jun 2026, Board
- Shares
- 10,000
- Price
- $34.90
- Value
- $349,000
- Manchester Keith SSale
30 Jun 2026, Board
- Shares
- 200,000
- Price
- $35.45
- Value
- $7.09M
- QVT Financial LP, Gold Daniel Allen, Manchester Keith SSale
30 Jun 2026, Board
- Shares
- 12,380
- Price
- $35.28
- Value
- $436,766
- Epperly Melissa B,Sale
29 Jun 2026, Board
- Shares
- 17,750
- Price
- $34.38
- Value
- $610,252
- QVT Financial LP, Gold Daniel Allen, Manchester Keith SSale
29 Jun 2026, Board
- Shares
- 800,000
- Price
- $34.55
- Value
- $27.64M
- QVT Financial LP, Gold Daniel Allen, Manchester Keith SSale
26 Jun 2026, Board
- Shares
- 625,783
- Price
- $34.00
- Value
- $21.28M
- Sukhatme MayukhSale
26 Jun 2026, President & CIO
- Shares
- 500,000
- Price
- $34.08
- Value
- $17.04M
- Sukhatme MayukhSale
25 Jun 2026, President & CIO
- Shares
- 500,000
- Price
- $34.13
- Value
- $17.07M
- Venker EricSale
24 Jun 2026, President & Immunovant CEO
- Shares
- 200,000
- Price
- $33.16
- Value
- $6.63M
- Venker EricSale
22 May 2026, President & Immunovant CEO
- Shares
- 200,000
- Price
- $30.27
- Value
- $6.05M
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Roivant Sciences
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 48
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- BeOne MedicinesONC $44.45B70
- Revolution MedicinesRVMD $38.14B41
- Celltrion068270.KS $35.82B64
- GenmabGMAB.CO $32.18B66
- InsmedINSM $25.9B43
- WuXi Biologics (Cayman)2269.HK $25.32B73
- United TherapeuticsUTHR $25.27B81
- IncyteINCY $24.81B70
ETFs that hold Roivant Sciences
Held by 31 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 1.74% | 0.35% | €1.25B |
| Invesco NASDAQ Next Generation 100 UCITS ETF AccEQQJ | 1.52% | 0.25% | €45.16M |
| iShares Healthcare Innovation UCITS ETF2B78 | 1.48% | 0.40% | €1.5B |
Show 5 more
| iShares MSCI USA Mid-Cap Equal Weight UCITS ETFQDVC | 0.38% | 0.20% | €272.21M |
| iShares MSCI World Momentum Factor Advanced UCITS ETFCBUH | 0.22% | 0.25% | €267.4M |
| iShares MSCI World Mid-Cap Equal Weight UCITS ETF USDIS3T | 0.14% | 0.30% | €411.06M |
| iShares Edge MSCI USA Momentum Factor UCITS ETFQDVA | 0.12% | 0.20% | €529.83M |
| First Trust US Large Cap Core AlphaDEX UCITS ETFFTGU | 0.09% | 0.75% | €142.73M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Mar 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 22 May 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.